Biopharma giant Abbvie has announced the acquisition of Allergan for $63 billion in cash and stock. Abbvie said the deal would be “transformational” for both companies, allowing Abbvie to diversify its business while focusing on scientific research and the company’s pipeline.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
The amount of data captured by pharma companies today is fast outpacing best use for it. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or missing a potential opportunity that their rivals seize. Stemming from Front Line Genomics’ […]
The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.
Takeda Pharmaceutical has announced the sizeable first sale in its proposed £10 billion-worth of assets to offset the debt it took on during its acquisition of Shire. The company announced it was divesting eye drug Xiidra to Novartis for $5.3bn total, and its TachoSil Fibrin Sealant Patch to Ethicon for $400 million in case.
Genetic research is a big data problem without researchers generally having access to this “big” genomic and medical data. Not only has it been nearly impossible to access enough relevant data to support research, but analysing the data has been slow and challenging due to its sheer volume. To counter this, in recent years a number of pharmaceutical companies have announced large-scale collaborations around genomic data to uncover novel drug targets, validate existing drug pipelines, predict response, and expand therapeutics use. We discuss some of the biggest and most recent.
Compression software company Petagene has announced the addition of “Petagene Protect” to its suite of genomic data projects, giving users the ability to encrypt and manage access to genomic data, as well as ensuring compliance with all relevant regulations.
SOPHiA GENETICS’ Solid Tumor Solution molecular diagnostic application has received CE-IVD designation. The application detects and characterises all types of genomic alteration in 42 clinically-relevant genes related to solid tumours across a number of cancer types.
Roche is set to pay $4.3bn for the acquisition of Spark Therapeutics, a gene therapy company that will put the pharma giant ahead in one of the biggest growing markets around.
The Festival has really captured the imagination of leading scientists – particularly in the UK. So much so, that increasingly we are lucky to attract incredible speakers who hugely enrich the experience of our attendees. This year is stronger than ever. We luckily got a chance to visit some of our top speakers before the […]
Genetics Unzipped, a new fortnightly podcast from the UK Genetics Society, has launched ahead of the society’s centenary celebrations throughout 2019. Presented by award-winning science writer and former Naked Genetics/Naked Scientists podcast host Kat Arney and produced by First Create The Media, Genetics Unzipped will bring you a wide range of stories from the world of genetics, genomics and DNA.
SOPHiA GENETICS has successfully completed a $77 million funding round, the company recently announced at the JP Morgan Healthcare Conference in San Francisco.
Bristol-Myers Squibb (BMS) has announced intentions to buy Celgene for $74bn. This transaction, the fourth largest such deal in pharma history, will give BMS access to several cancer franchises, including experimental cell therapies which attack tumours.
The latest annual report from Trinity Partners has found that orphan disease drugs often perform poorly at launch and continue to underachieve after three years of sales. At the other end of the spectrum, the most successful drugs on the market were for non-orphan diseases such as cancer and HIV.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!